RT Journal Article
SR Electronic
T1 Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 707
OP 714
DO 10.3949/ccjm.76a.09116
VO 76
IS 12
A1 Lawrence D. Lazar
A1 A. Michael Lincoff
YR 2009
UL http://www.ccjm.org/content/76/12/707.abstract
AB Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention. In a large clinical trial (N Engl J Med 2007; 357:2001–2005), prasugrel was superior to clopidogrel (Plavix), another drug of its class, in this situation. However, bleeding complications were more frequent with prasugrel, and so this drug should be avoided in patients at higher risk of bleeding.